Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
– Expect to complete SER-109 Biologics License Application filing in the coming weeks – – Reported confirmatory SER-109 Phase 3 study results, including in individuals with a first recurrence of C. difficile infection – – Strengthened balance sheet with $100 million registered direct equity offering – Conference call at 8:30 a.m. ET today – CAMBRIDGE, … [Read more…]